Status:
COMPLETED
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This 4 arm study will assess the optimal starting dose of Mircera in the treatment of anemia in patients with non-small cell lung cancer receiving first line myelosuppressive chemotherapy. Patients wi...
Eligibility Criteria
Inclusion
- \>=18 years of age;
- stage III or IV non-small cell lung cancer receiving first line myelosuppressive chemotherapy;
- myelosuppressive chemotherapy scheduled for at least 9 weeks;
- anemia at screening visit.
Exclusion
- transfusion of red blood cells during the 4 weeks prior to first planned dose of study medication;
- iron deficiency anemia, or anemia caused by gastrointestinal bleeding;
- prior treatment with Mircera.
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
153 Patients enrolled
Trial Details
Trial ID
NCT00327535
Start Date
May 1 2006
End Date
May 1 2007
Last Update
August 11 2016
Active Locations (68)
Enter a location and click search to find clinical trials sorted by distance.
1
East Bentleigh, Australia, VIC 3165
2
Kurralta Park, Australia, 5037
3
Milton, Australia, 4064
4
Linz, Austria, 4020